Cambridge Investment Research Advisors
PTX

Cambridge Investment Research Advisors’s Pernix Therapeutics Holdings, Inc. PTX Stock Holding History

Cambridge Investment Research Advisors’s Portfolio PTX Stock Details PTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-2,800
Closed -$17K – 1871
2016
Q3 		$17K Buy
2,800
+100
+4% +$616 ﹤0.01% 1730
2016
Q2 		$12K Buy
+2,700
New +$17.6K ﹤0.01% 1546

Other funds holding PTX

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GC
Globeflex Capital San Diego, California $661M AUM 50.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 19.31% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Cambridge Investment Research Advisors's PTX Position: Q4 2016 in Review

Cambridge Investment Research Advisors sold out of Pernix Therapeutics Holdings, Inc. (PTX) in Q4 2016, closing a stake of 2,800 shares — an estimated $17K sold.

Cambridge Investment Research Advisors first reported a position in PTX in Q2 2016 and held it in 2 quarters. The position peaked at $17K in Q3 2016. 34 funds tracked by Wall St. Rank hold PTX as of Q4 2016.

  • Cambridge Investment Research Advisors reported no remaining Pernix Therapeutics Holdings, Inc. position as of Q4 2016 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 2,800 Pernix Therapeutics Holdings, Inc. shares in Q4 2016, an estimated $17K.
  • Cambridge Investment Research Advisors first reported a position in Pernix Therapeutics Holdings, Inc. in Q2 2016 and held it in 2 quarters.
  • Cambridge Investment Research Advisors's Pernix Therapeutics Holdings, Inc. position peaked at $17K in Q3 2016.
  • 34 funds tracked by Wall St. Rank held Pernix Therapeutics Holdings, Inc. as of Q4 2016.

Based on Cambridge Investment Research Advisors's 13F filing for Q4 2016, filed 13 Feb 2017.